Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $17.07 down -0.70% from its previous closing price of $17.19. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 0.99 million shares were traded. ACAD stock price reached its highest trading level at $17.345 during the session, while it also had its lowest trading level at $17.01.
Ratios:
For a deeper understanding of Acadia Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 168.93. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.42. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 12, 2024, Reiterated its Buy rating but revised its target price to $32 from $36 previously.
On March 12, 2024, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $39 to $25.
On January 30, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $40.Robert W. Baird initiated its Outperform rating on January 30, 2024, with a $40 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 08 ’24 when DAVIS STEPHEN sold 26,574 shares for $17.87 per share. The transaction valued at 474,877 led to the insider holds 144,267 shares of the business.
Schneyer Mark C. sold 2,716 shares of ACAD for $48,535 on Apr 08 ’24. The EVP, CHIEF FINANCIAL OFFICER now owns 28,742 shares after completing the transaction at $17.87 per share. On Apr 08 ’24, another insider, Teehan Brendan, who serves as the EVP, COO, HEAD OF COMMERCIAL of the company, sold 2,568 shares for $17.87 each. As a result, the insider received 45,890 and left with 38,796 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 2812657920 and an Enterprise Value of 2430989824. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.87 while its Price-to-Book (P/B) ratio in mrq is 6.51. Its current Enterprise Value per Revenue stands at 3.346 whereas that against EBITDA is -35.841.
Stock Price History:
Over the past 52 weeks, ACAD has reached a high of $33.99, while it has fallen to a 52-week low of $16.60. The 50-Day Moving Average of the stock is -20.04%, while the 200-Day Moving Average is calculated to be -31.13%.
Shares Statistics:
For the past three months, ACAD has traded an average of 1.79M shares per day and 1269190 over the past ten days. A total of 164.65M shares are outstanding, with a floating share count of 163.46M. Insiders hold about 0.80% of the company’s shares, while institutions hold 97.04% stake in the company. Shares short for ACAD as of 1711584000 were 11197462 with a Short Ratio of 6.24, compared to 1709164800 on 10805509. Therefore, it implies a Short% of Shares Outstanding of 11197462 and a Short% of Float of 9.08.
Earnings Estimates
Currently, ACADIA Pharmaceuticals Inc. analysts are dedicated to thoroughly evaluating and rating the performance of Acadia Pharmaceuticals Inc (ACAD) in the stock market.The consensus estimate for the next quarter is $56.48, with high estimates of $9.17 and low estimates of $26.46.
